Benzinga · Oct 21, 2026
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $118 to $96.
AB
NASDAQ · ABVX
Abivax S.A.
Healthcare · Biotechnology
$84.91
Up+$3.43 (+4.04%)
Updated Nov 3, 2026, 8:29 PM
SID Score
3.8/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 7.95B
- P/E ratio
- -33.3
- Dividend yield
- 0.00%
- 52-week range
- $69.81 – $148.83
- Volume
- 731.02K
- Avg. volume
- 1.52M
Price performance · ABVX
ABVX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
ABVX closed at $84.91 after 21 trading sessions, down 7.43% for the selected period.
- Last close
- $84.91
- Period change
- -7.43%
- Period low
- $84.91
- Period high
- $93.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $87.32 | $87.50 | $83.55 | $84.91 | 731.02K |
| Oct 30, 2026 | $87.66 | $88.90 | $85.81 | $86.59 | 843.41K |
| Oct 29, 2026 | $89.85 | $92.09 | $88.3946 | $89.06 | 595.98K |
| Oct 28, 2026 | $87.91 | $90.9787 | $87.03 | $89.84 | 536.77K |
| Oct 27, 2026 | $86.63 | $89.40 | $86.14 | $87.00 | 740.27K |
| Oct 26, 2026 | $88.01 | $88.46 | $86.2489 | $86.50 | 423.69K |
| Oct 23, 2026 | $89.60 | $89.60 | $87.03 | $88.01 | 432.47K |
| Oct 22, 2026 | $92.29 | $93.98 | $88.15 | $90.23 | 896.11K |
| Oct 21, 2026 | $93.86 | $96.39 | $93.05 | $93.49 | 948.09K |
| Oct 20, 2026 | $89.605 | $94.19 | $88.44 | $92.59 | 1.6M |
| Oct 19, 2026 | $88.00 | $89.71 | $85.35 | $87.49 | 1.58M |
| Oct 16, 2026 | $91.48 | $91.48 | $86.85 | $88.13 | 1.45M |
| Oct 15, 2026 | $88.36 | $92.81 | $88.0306 | $92.38 | 1.52M |
| Oct 14, 2026 | $86.12 | $89.38 | $85.88 | $87.98 | 1.13M |
| Oct 13, 2026 | $85.92 | $86.86 | $84.51 | $86.22 | 993.31K |
| Oct 12, 2026 | $87.32 | $87.91 | $86.40 | $86.94 | 658.94K |
| Oct 9, 2026 | $90.21 | $90.56 | $87.39 | $88.15 | 885.32K |
| Oct 8, 2026 | $86.70 | $89.10 | $84.11 | $89.05 | 2.11M |
| Oct 7, 2026 | $86.86 | $88.4599 | $86.00 | $87.01 | 1.39M |
| Oct 6, 2026 | $93.67 | $93.67 | $87.83 | $88.22 | 2M |
| Oct 5, 2026 | $92.27 | $92.61 | $89.40 | $91.73 | 840.31K |
Latest ABVX news
The latest Smart Investors Daily articles mentioning ABVX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABVX research
Overview
Company profile and research snapshot.
Company profile
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $130.86
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | STIFEL EUROPE | Buy | — |
| Sep 22, 2026 | BTIG | Buy | — |
| Sep 22, 2026 | ODDO BHF | Buy | — |
| Jul 6, 2026 | ODDO BHF | Buy | — |
| Jul 5, 2026 | ODDO BHF | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 20, 2026
Guggenheim Reiterates Buy on Abivax, Maintains $175 Price Target
Guggenheim analyst Yatin Suneja reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Yahoo · Oct 7, 2026
Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management’s Multi-Strategy Composite returned -12.7%, trailing the Russell 2000 (-7.2%), Russell Microcap (-7.4%), and S&P 500 (+2.4%). Since its January 14, 2026, inception, the composite has returned -26.2%, compared […]
Yahoo · Sep 30, 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
